Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Pulford, DJ; Harter, P; Floquet, A; Barrett, C; Suh, DH; Friedlander, M; Arranz, JA; Hasegawa, K; Tada, H; Vuylsteke, P; Mirza, MR; Donadello, N; Scambia, G; Johnson, T; Cox, C; Chan, JK; Imhof, M; Herzog, TJ; Calvert, P; Wimberger, P; Berton-Rigaud, D; Lim, MC; Elser, G; Xu, CF; du Bois, A.

Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study

BMC MEDICAL ETHICS. 2016; 17: Nº de citas: 1 [doi:10.1186/s12910-016-0144-y]

Press, MF; Sauter, G; Buyse, M; Fourmanoir, H; Quinaux, E; Tsao-Wei, DD; Eiermann, W; Robert, N; Pienkowski, T; Crown, J; Martin, M; Valero, V; Mackey, JR; Bee, V; Ma, YL; Villalobos, I; Campeau, A; Mirlacher, M; Lindsay, MA; Slamon, DJ.

HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials

JOURNAL OF CLINICAL ONCOLOGY. 2016; 34(29): 3518 Nº de citas: 122 [doi:10.1200/JCO.2016.66.6693]

Awada, A; Cortes, J; Martin, M; Aftimos, P; Oliveira, M; Lopez-Tarruella, S; Espie, M; Lardelli, P; Extremera, S; Fernandez-Garcia, EM; Delaloge, S.

Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene

CLINICAL BREAST CANCER. 2016; 16(5): 364-371 Nº de citas: 3 [doi:10.1016/j.clbc.2016.05.005]

Porta-Sales, J; Perez, C; Escobar, Y; Martinez, V.

Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2016; 18(9): 945-954 Nº de citas: 19 [doi:10.1007/s12094-015-1468-7]

Dalgleish, AG; Stebbing, J; Adamson, DJA; Arif, SS; Bidoli, P; Chang, D; Cheeseman, S; Diaz-Beveridge, R; Fernandez-Martos, C; Glynne-Jones, R; Granetto, C; Massuti, B; McAdam, K; McDermott, R; Martin, AJM; Papamichael, D; Pazo-Cid, R; Vieitez, JM; Zaniboni, A; Carroll, KJ; Wagle, S; Gaya, A; Mudan, SS.

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

BRITISH JOURNAL OF CANCER. 2016; 115(7): 789-796 Nº de citas: 48 [doi:10.1038/bjc.2016.271]

Jerusalem, G; Mariani, G; Ciruelos, EM; Martin, M; Tjan-Heijnen, VCG; Neven, P; Gavila, JG; Michelotti, A; Montemurro, F; Generali, D; Simoncini, E; Lang, I; Mardiak, J; Naume, B; Camozzi, M; Lorizzo, K; Bianchetti, S; Conte, P.

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)

ANNALS OF ONCOLOGY. 2016; 27(9): 1719-1725 Nº de citas: 55 [doi:10.1093/annonc/mdw249]

Gonzalez-Rivera M; Picornell AC; Alvarez EL; Martin M.

A Cross-Sectional Comparison of Druggable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells, and Cell-Free Circulating DNA in Patients with Metastatic Breast Cancer: The MIRROR Study Protocol.

Jmir Research Protocols. 2016; 5(3): Nº de citas: 6 [doi:10.2196/resprot.6024]

Ramos-Medina, R; Moreno, F; Lopez-Tarruella, S; del Monte-Millan, M; Marquez-Rodas, I; Duran, E; Jerez, Y; Garcia-Saenz, JA; Ocana, I; Andres, S; Massarrah, T; Gonzalez-Rivera, M; Martin, M.

Review: circulating tumor cells in the practice of breast cancer oncology

CLINICAL & TRANSLATIONAL ONCOLOGY. 2016; 18(8): 749-759 Nº de citas: 5 [doi:10.1007/s12094-015-1460-2]

Martin, M; Lopez-Tarruella, S; Gilarranz, YJ.

Endocrine therapy for hormone treatment-naive advanced breast cancerf

BREAST. 2016; 28: 161-166 Nº de citas: 9 [doi:10.1016/j.breast.2016.05.015]

Garcia-Donas, J; Beuselinck, B; Inglada-Perez, L; Grana, O; Schoffski, P; Wozniak, A; Bechter, O; Apellaniz-Ruiz, M; Leandro-Garcia, LJ; Esteban, E; Castellano, DE; del Alba, AG; Climent, MA; Hernando, S; Arranz, JA; Morente, M; Pisano, DG; Robledo, M; Rodriguez-Antona, C.

Deep sequencing reveals microRNAs predictive of antiangiogenic drug response

Jci Insight. 2016; 1(10): Nº de citas: 40 [doi:10.1172/jci.insight.86051]

Martin-Broto, J; Pousa, AL; de las Penas, R; del Muro, XG; Gutierrez, A; Martinez-Trufero, J; Cruz, J; Alvarez, R; Cubedo, R; Redondo, A; Maurel, J; Carrasco, JA; Lopez-Martin, JA; Sala, A; Meana, JA; Ramos, R; Martinez-Serra, J; Lopez-Guerrero, JA; Sevilla, I; Balana, C; Vaz, A; De Juan, A; Alemany, R; Poveda, A.

Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study

JOURNAL OF CLINICAL ONCOLOGY. 2016; 34(19): 2294 Nº de citas: 63 [doi:10.1200/JCO.2015.65.3329]

Bermejo-Martin, JF; Avila-Alonso, A; Gonzalez-Rivera, M; Tamayo, E; Eiros, JM; Almansa, R.

Postbooster Antibodies from Humans as Source of Diphtheria Antitoxin

EMERGING INFECTIOUS DISEASES. 2016; 22(7): 1265-1267 Nº de citas: 5 [doi:10.3201/eid2207.151670]

Martin, M; Fumoleau, P; Dewar, JA; Albanell, J; Limentani, SA; Campone, M; Chang, JC; Patre, M; Strasak, A; de Haas, SL; Xu, J; Garcia-Saenz, JA.

Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study

ANNALS OF ONCOLOGY. 2016; 27(7): 1249-1256 Nº de citas: 50 [doi:10.1093/annonc/mdw157]

Martin, AJM; Alfonso, PG; Ruperez, AB; Jimenez, MM.

Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2

Oncology Letters. 2016; 12(1): 727-730 Nº de citas: 8 [doi:10.3892/ol.2016.4667]

de Maturana, EL; Picornell, A; Masson-Lecomte, A; Kogevinas, M; Marquez, M; Carrato, A; Tardon, A; Lloreta, J; Garcia-Closas, M; Silverman, D; Rothman, N; Chanock, S; Real, FX; Goddard, ME; Malats, N; SBC EPICURO Study Investigators.

Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models

BMC CANCER. 2016; 16: Nº de citas: 4 [doi:10.1186/s12885-016-2361-7]

Cortejoso, L; Garcia-Gonzalez, X; Garcia, MI; Garcia-Alfonso, P; Sanjurjo, M; Lopez-Fernandez, LA.

Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines

PHARMACOGENOMICS. 2016; 17(9): 979-984 Nº de citas: 40 [doi:10.2217/pgs-2016-0006]

Espinosa, E; Soriano, V; Malvehy, J; Berrocal, A; de Prado, PM; Quindos, M; Soria, A; Marquez-Rodas, I; Palacio, I; Cerezuela, P; Lopez-Vivanco, G; Alonso, L; Samaniego, E; Ballesteros, A; Puertolas, T; Diaz-Beveridge, R; de la Cruz-Merino, L; Castro, RL; Lopez, RL; Stevinson, K; del Barrio, P; Tornamira, MV; Guillem, V; Martin-Algarra, S.

Treatment patterns of adjuvant interferon-alpha 2b for high-risk melanoma: a retrospective study of the Grupo Espanol Multidisciplinar de Melanoma - Prima study

MELANOMA RESEARCH. 2016; 26(3): 278-283 Nº de citas: 9 [doi:10.1097/CMR.0000000000000254]

Mackey, JR; Pienkowski, T; Crown, J; Sadeghi, S; Martin, M; Chan, A; Saleh, M; Sehdev, S; Provencher, L; Semiglazov, V; Press, MF; Sauter, G; Lindsay, M; Houe, V; Buyse, M; Drevot, P; Hitier, S; Bensfia, S; Eiermann, W.

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial

ANNALS OF ONCOLOGY. 2016; 27(6): 1041-1047 Nº de citas: 55 [doi:10.1093/annonc/mdw098]